Skip to main content
Quantum Biopharma Ltd. logo

Quantum Biopharma Ltd. — Investor Relations & Filings

Ticker · QNTM ISIN · CA74764Y2050 US Manufacturing
Open in API
Filings indexed 339 across all filing types
Latest filing 2025-05-28 Regulatory Filings
Country US United States of America
Listing US QNTM

About Quantum Biopharma Ltd.

https://www.quantumbiopharma.com/

Quantum Biopharma Ltd. is a biopharmaceutical company developing a portfolio of assets for neurodegenerative, neuropsychiatric, and inflammatory disorders. The company's lead pharmaceutical candidate is Lucid-MS, a patented, first-in-class neuroprotective compound for Multiple Sclerosis that targets myelin repair and has completed Phase 1 human clinical trials. Alongside its drug development pipeline, Quantum Biopharma is launching unbuzzd™, a functional beverage designed to support mental alertness and detoxification following alcohol consumption. The company's dual strategy focuses on both advanced pharmaceutical research and development and consumer wellness products.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Quantum BioPharma Ltd., pursuant to SEC rules. It includes a press release as Exhibit 99.1 dated May 28, 2025. The text does not contain any financial statements or detailed report content but rather references the press release attached. The document length is only 2710 characters, which is short and consistent with an announcement rather than a full report. According to the MENU VS MEAL RULE, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other categories and includes Form 6-K filings with press releases.
2025-05-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Quantum BioPharma Ltd., pursuant to SEC rules. It is a report that includes a press release as Exhibit 99.1 dated May 21, 2025. The document length is 2710 characters, which is relatively short and primarily serves to submit the press release to the SEC. There is no substantive financial data, detailed analysis, or comprehensive report content within this filing itself. According to the MENU VS MEAL RULE, this is an announcement or submission of a press release rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-05-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Quantum BioPharma Ltd., with the SEC. It is a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 for May 2025. The text indicates that the main content is a press release dated May 20, 2025, attached as Exhibit 99.1. The document itself is short (2710 characters) and primarily serves to submit the press release to the SEC. There is no substantive financial data or detailed report content within this filing. According to the rules, such filings that mainly attach or reference a press release or report and are short in length should be classified as Regulatory Filings (RNS), as they do not constitute the report itself but rather a regulatory submission of an announcement or press release.
2025-05-20 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It includes a press release dated May 19, 2025, attached as Exhibit 99.1. The text does not contain detailed financial statements or substantive financial data but rather references the press release. The document length is 2710 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-05-19 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC to furnish reports or other documents that the issuer must make public under home country laws or exchange rules. The text indicates that the main content is a press release dated May 16, 2025, attached as Exhibit 99.1. The document length is only 2710 characters, which is quite short and primarily serves to submit the press release. There is no substantive financial data, detailed report, or analysis included. According to the rules, such a short document that mainly attaches or references a press release or report is classified as a Regulatory Filing (RNS) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-05-16 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Quantum BioPharma Ltd., with the SEC. It includes unaudited condensed consolidated financial statements and Management's Discussion and Analysis (MD&A) for the three months ended March 31, 2025, which corresponds to an interim/quarterly period. The presence of financial statements and MD&A for a quarterly period indicates this is an Interim / Quarterly Report. The document length is 2603 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-05-14 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.